Lung Cancer
Advertisement
Arthi Sridhar, MD, discusses the real-world study, which was presented at the IASLC 2024 World Conference on Lung Cancer.
Learn what the global survey showed about the rates of biomarker testing and the remaining barriers to implementation.
Michael R. Gieske, MD, discusses the lung cancer screening initiative, which has been recognized on a national level.
The three-year survival rate in the 2020 cohort of patients with NSCLC was more than double that of the 2000 cohort.
The meeting will be held September 12-15, 2026, in Seoul, South Korea.
Olvimulogene nanivacirepvec is a proprietary, modified oncolytic vaccinia virus.
The registry, launched by the Florez Lab in 2023, is collecting data from around the world.
Indoor air pollutants can come from multiple sources and can be risk factors for developing lung cancer.
The 5-year scoping review provided insights on the different abstracts and educational content presented at 12 meetings.
Officials plan to submit a supplemental New Drug Application for the use of the combination therapy in this setting.
The FDA approved Optune Lua, a wearable TTFields treatment, for concurrent use with PD-1/PD-L1 inhibitors or docetaxel.
Shirish M. Gadgeel, MD, shares how treatment options and patient outcomes have evolved since he began practicing.
Researchers conducted an analysis of CheckMate 227 and CheckMate 9LA studies to evaluate pooled patient outcomes.
Dr. Gieske shares what the White Ribbon Project means to him as a lung cancer clinician.
Gene Ho, MPH, discusses real-world data on adverse events and survival outcomes with immunotherapy for NSCLC.
Researchers presented results from the randomized controlled trial of mPATH-Lung at the CHEST Annual Meeting.
Jamie L. Studts, PhD, discusses the use of the QUILS™ system in Kentucky and the importance of community engagement.
Annette McWilliams, MBBS, FRACP, PhD, discusses her IASLC Presidential Symposium presentation on the study.
Jill Feldman, a patient advocate, discusses how the lexicon can improve communication and empower patients.
The CheckMate 77T trial evaluated the efficacy of adjuvant and neoadjuvant nivolumab in resectable, untreated NSCLC.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.